Zepbound Microdosing: 4 Real Options, Since Lilly Doesn't Sell One

Where can you get microdose tirzepatide? The 4 options, one by one

Three sellers use compounded tirzepatide, the medicine in Zepbound, made by a pharmacy for one patient. Compounded medicine is not FDA-approved. The fourth option is real Zepbound at its lowest dose. Start with the line that sounds like you:

• Lowest monthly price: Mochi Health, about $170 a month at the lowest dose.
• Lowest if you prepay a year: BetterMe Rx, about $185 a month.
• Holding results you already reached: Fridays, about $200 a month.
• You want the FDA-approved drug: Zepbound 2.5 mg from Lilly, about $300 a month.
• With insurance or Medicare: look at full-dose Zepbound first. The savings card or Medicare's GLP-1 Bridge can cost far less.

Mochi Health: the lowest monthly price

Mochi has a microdosing plan for compounded tirzepatide. It prices medicine by dose, so the microdose is the cheapest step of its normal ladder. Tirzepatide starts at about $90 a month, plus about $80 for the membership. The first month of membership is free on the monthly plan.

Mochi works as a pharmacy marketplace, so these are floor prices that can vary. A prepaid year of membership brings the lowest dose to about $140 a month.

One thing to know: Eli Lilly sued Mochi in April 2025 over how it marketed compounded tirzepatide. In April 2026, a federal judge let Lilly's false-advertising claims go forward. Mochi calls the suit a reaction to competition, and no court has found wrongdoing. Our Mochi Health review has the details.

BetterMe Rx: one price at every dose

BetterMe Rx sells a separate microdosing plan for people who want to lose 5 to 20 pounds or keep weight off. The tirzepatide shot costs about $235 month to month. On a 12-month plan paid upfront, it is about $185 a month. Visits and shipping are included, and the price stays the same as the dose changes.

Two cautions. Its microdosing page quotes weight loss of up to 22%, a figure from full-dose trials, not from microdoses. And nothing is refunded once an order is processed.

Fridays: a microdose for holding results

Fridays sells a weekly compounded tirzepatide microdose for about $200 a month, apart from its weight-loss plans. It says the plan suits people already stable on a GLP-1, without a weight-loss focus. Its own page says these compounded formulas have not been studied for those outcomes.

Zepbound 2.5 mg from Lilly: the FDA-approved starting dose

Lilly sells Zepbound at self-pay prices through LillyDirect and local pharmacies. The 2.5 mg starting dose costs about $300 a month, as a KwikPen or a vial. There is no refill-timing condition at this dose.

The catch is the label. It says 2.5 mg is for starting treatment and is not meant for long-term weight management. Staying on it for good is off-label, so you need a prescriber who agrees.

For more providers and the full tirzepatide picture, see tirzepatide microdosing.

Is there a real Zepbound microdose product?

No. Zepbound is Eli Lilly's brand of tirzepatide, FDA-approved for weight management. Its doses run from 2.5 mg to 15 mg. Lilly has never sold anything below 2.5 mg.

What ads call "Zepbound microdosing" is almost always compounded tirzepatide. A seller that uses the Zepbound name for a compounded product is using the wrong word. For the full naming and legal picture, see compounded Zepbound: what's really sold.

What does tirzepatide microdosing cost per month and per year?

Here is a rough first year at a steady low dose:

• Mochi Health: about $1,950 to $2,030 at the lowest dose, or about $1,670 with a prepaid year of membership.
• BetterMe Rx: about $2,220 paid upfront for 12 months, or about $2,820 month to month.
• Fridays: about $2,380.
• Zepbound 2.5 mg from Lilly: about $3,890 for 13 four-week fills. Lilly's self-pay offer ends Dec 31, 2026, and its KwikPen terms cap the offer at 11 fills a calendar year.

Full-dose brand-name Zepbound, for comparison:

• With insurance that covers Zepbound: as little as $25 a month with Lilly's savings card.
• On Medicare: $50 a month for the Zepbound KwikPen through the GLP-1 Bridge, from July 2026 to December 2027, if you qualify.
• Lilly self-pay at higher doses: about $400 at 5 mg and about $450 from 7.5 mg, if you refill within 45 days. Late refills cost about $500 at 7.5 mg and about $700 from 10 mg.
• List price, no program: about $1,085 a month for the single-dose pen.

None of these totals include lab tests. For every Zepbound price path, see Zepbound cost.

Zepbound's real dose ladder, and where a microdose sits

Zepbound starts at 2.5 mg. The dose can rise in 2.5 mg steps, each after at least four weeks. A compounded microdose usually sits below the first step.

For units, vials and missed doses, see the complete Zepbound dosage chart.

Is compounded tirzepatide microdosing legal right now?

Yes, on a narrow basis. The FDA ended the tirzepatide shortage in December 2024, which ended mass compounding. A licensed pharmacy can still make tirzepatide for one patient on a prescription, including at a low dose.

On April 30, 2026, the FDA proposed not adding tirzepatide, semaglutide and liraglutide to the list that large outsourcing pharmacies, called 503B, can compound from. Comments closed July 30, 2026, and there is no final decision yet.

Is there real science behind tirzepatide microdosing?

Not yet. No trial has tested a long-term tirzepatide dose below 2.5 mg. Lilly's first human study used smaller doses, but only once or for four weeks, in healthy people. In SURMOUNT-1, the trial behind Zepbound, weight loss grew with the dose. People lost about 15% on 5 mg and about 21% on 15 mg over 72 weeks, against about 3% on placebo.

Harvard endocrinologist Dr. Jody Dushay wrote in STAT News in May 2026 that there are no legitimate long-term data behind GLP-1 microdosing.

Are the side effects gentler at a microdose?

Maybe, but it is not proven. In the Zepbound trials, nausea, diarrhea and constipation were worst right after a dose increase. A smaller, steady dose could mean fewer rough weeks. But no trial has measured side effects on a long-term dose below 2.5 mg.

Some risks do not shrink with the dose. Zepbound's boxed warning about thyroid C-cell tumors, seen in rodents, applies to the medicine itself. The label also lists hair loss, reported by 7.1% of women on Zepbound against 1.3% on placebo. Our Zepbound side effects guide covers the full list.

Can you use a microdose to keep weight off?

That is the use Fridays and BetterMe Rx aim at. The evidence is thin. A small 2025 report in the journal Obesity looked at spacing full doses further apart instead of shrinking them. It covered two patients plus a computer model, so it is an idea to test, not a result.

In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained about 14% of their weight over the next year. People who stayed on it lost about 5.5% more. So any step down is a decision to make with your prescriber.

Is a low dose the right start for you in perimenopause?

Many women notice more nausea and bloating in perimenopause. So a gentler start is appealing, and a slower climb can mean fewer rough early weeks.

The trade-off is results. SURMOUNT-1 showed a real gap between the low and high doses. If real weight or metabolic change is the goal, a standard climb to a maintenance dose has stronger evidence. Muscle matters more after 40, and GLP-1s and muscle loss in perimenopause covers how to protect it.

How to tell a legitimate low-dose plan from a DIY red flag

What matters most is who manages the dose. A legitimate plan comes from a licensed prescriber and a named pharmacy. Your provider sets the dose and can change it.

• "Compounded Zepbound" as a product name. Legitimate sellers say compounded tirzepatide.
• No named pharmacy. A real program can tell you which licensed pharmacy fills your prescription.
• No clinician review before shipping. That is a hard stop, whatever the price.
• Drawing your own smaller dose from a Zepbound pen or vial. Lilly says its single-dose vials have no preservative and should not be split.